Results 31 to 40 of about 50,237 (216)
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
Cancer Biology & Medicine, 2020 Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally ...
Olivia Leblanc +14 more
doaj +1 more source
BMJ Open, 2022 Objective The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor ...
David Malka +10 more
doaj +1 more source
In vivo efficacy of Palbociclib and Cetuximab in CF555 chordoma xenograft model_CF40
, 2021 DrugTargetsPalbociclib + CetuximabCDK4/6 + EGFRDose75mg/kg (Palbociclib) 20mg/kg (Cetuximab)RoutePO (Palbociclib) IP (Cetuximab)Scheduleqd to end (Palbociclib) 2xwklyx6 (Cetuximab) Duration of treatment42 dStrain of miceAthymic NudeTGI (day)98% (Day 42)p-
Dan Freed (4391989)
core +1 more source
Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models
BMC Research Notes, 2011 Background The binding of EGFR and its ligands leads to autophosphorylation of receptor tyrosine kinase as well as subsequent activation of signal transduction pathways that are involved in regulating cellular proliferation, differentiation, and survival.
Matsuo Teppei +5 more
doaj +1 more source
In vivo efficacy of Abemaciclib and Cetuximab in SF8894 chordoma xenograft model_CF41
, 2021 DrugTargetsAbemaciclib + CetuximabCDK4/6 + EGFRDose50mg/kg (Abemaciclib) 20mg/kg (Cetuximab)RoutePO (Abemaciclib) IP (Cetuximab)Scheduleqd to end (Abemaciclib) 2xwklyx6 (Cetuximab) Duration of treatment42 dStrain of miceAthymic NudeTGI (day)49% (Day 41)p-
Dan Freed (4391989)
core +1 more source
Cetuximab-sulfo-SMCC-protamine ability to transport two independent siRNAs.
, 2018 A-I. Alexa 488 and Alexa 555 control-siRNA were mixed, coupled to cetuximab-sulfo-SMCC-protamine and incubated with the indicated cell lines at 60 nM end concentration overnight (Fig 1 A to I) or 48 h (J to R).
Wolfgang Hartmann (38453) +9 more
core +1 more source
Cetuximab associated dermal filler reaction
, 2019 A 52-year-old male patient with hyaluronic acid-based dermal fillers injected in his cheeks was diagnosed with glossotonsillary malignancy, and managed with concurrent cetuximab (epidermal growth factor receptor inhibitor) and radiation therapy.
Dzienis, Marcin +1 more
core +1 more source
The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab
Laboratory Animal Research, 2018 This study investigated the anti-cancer potential of a near-infrared fluorescence (NIRF) molecule conjugated with Cetuximab (Cetuximab-NIRF) in six-week-old female BALB/c athymic (nu+/nu+) nude mice. A431 cells were cultured and injected into the animals
Ji Young Yun +5 more
doaj +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, EarlyView.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer
Advanced Science, EarlyView.The mechanisms of SeNPs therapy in cancer treatment, encompass three parallel actions: (1) seleno‐amino acids, key metabolites, upregulate GPX2 expression, thereby inhibiting tumor metastasis via the GPX2‐HIF1α‐VEGF signaling pathway; (2) selenite (SeO32−), an inorganic metabolite, forms hydrogen bonds with amino acid residues 13–17 of the KRAS G13D ...
Xiaoting Liu +13 more
wiley +1 more source